Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based research firm Ossianix and Denmark’s Lundbeck have agreed to expand and extend a strategic research collaboration to deliver next generation CNS biotherapeutics.
Subscribe to our email newsletter
As part of this collaboration, Ossianix’s new single Blood Brain Barrier (BBB) targeting domain antibody platform that is based on the shark VNAR structure will be used for the therapeutics.
The technology has been developed for the delivery of biopharmaceuticals including antibodies to treat CNS disorders.
Lundbeck Global Research senior vice-president Kim Andersen said: "The delivery of biopharmaceuticals across the BBB remains a key area for us and we hope that with Ossianix we can make leaps forward for the benefit of patients suffering from brain diseases."
Ossianix’s BBB targeting technology will give Lundbeck access to a patented suite of cross species reactive VNAR tools that allow designing products according to the therapeutic needs of an individual.
Both the companies will work on multiple targets that are in line with Lundbeck’s therapeutic goals.
Additionally, the collaboration will also focus on the ligand-gated P2X3 ion channel expressed on sensory neurons for the treatment of neuropathic pain.
While a joint research committee will manage the projects, the research plan with development and regulatory milestones will be funded by Lundbeck.
An additional equity investment will be provided for Ossianix to advance its own therapeutic programs.
The expansion and extension of the strategic research collaboration with Lundbeck follows a previous equity investment by Ossianix in 2012 and a research collaboration in 2013.